This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lourdes Tamayo, MD; Dulce M. Ortiz, MD; Luz Orozco-Covarrubias, MD; Carola Durán-McKinster, MD; Maria Antonieta Mora, MD; Estrella Avila, MD; Fernanda Teixeira, MD; Ramón Ruiz-Maldonado, MD

Arch Dermatol. 1997;133(12):1567-1571.

Abstract
Background
Because of their size and the possibility of complications, giant hemangiomas represent a therapeutic challenge. Various forms of treatment have been used, with variable results, including surgery, embolization, lasers, pentoxifylline, and corticosteroids. Interferon alfa has been used successfully to treat life-threatening hemangiomas, possibly by means of its antiangiogengenic activity.

Observations
We treated 7 infants with organ-interfering and/or life-threatening giant hemangiomas with subcutaneous injections of 3 million U/m² per day of interferon alfa-2b during the first month and subsequently every 48 to 72 hours, depending on the evolution in each case. The treatment lasted from 3 to 12 months. In 2 patients, interferon alfa-2b was administered while prednisone therapy was being tapered. In all 7 patients, there was considerable reduction of the volume of the hemangiomas and remission of their complications. All patients presented with fever, neutropenia, and an increase in serum aminotransferase levels. The patients who received interferon alfa-2b and prednisone seemed to improve at a faster rate.

Conclusions
Interferon alfa-2b is a good option for the treatment of patients with steroid-resistant, organ-interfering and/or life-threatening giant hemangiomas. In our experience, the adverse effects were transient and minor and did not require the interruption of the treatment.

Arch Dermatol. 1997;133:1567-1571

Author Affiliations
From the Departments of Dermatology (Drs Tamayo, Ortiz, Orozco-Covarrubias, Durán-McKinster, and Ruiz-Maldonado), Radiology (Dr Mora), and Nuclear Medicine (Dr Avila), National Institute of Pediatrics, and the Department of Dermatology, General Hospital "Dr Manuel Gea González" (Dr Teixeira), Mexico City, Mexico.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hemangiomas: An Overview
Sundine and Wirth
CLIN PEDIATR 2007;46:206-221.
 

Hemangiomas in Children
Drolet et al.
NEJM 1999;341:173-181.
FULL TEXT  

Caution With Regard to the Efficacy of Interferon Alfa-2b in the Treatment of Giant Hemangiomas
Leaute-Labreze et al.
Arch Dermatol 1998;134:1297-1298.
FULL TEXT  

Which Hemangiomas to Treat--and How?
Frieden
Arch Dermatol 1997;133:1593-1595.
ABSTRACT